drug

The Boston-based Institute for Clinical and Economic Review (ICER) sells itself as an independent source of information on the value of pharmaceuticals. But earlier this month, their bias was again evident when they tried to kneecap a drug for a dreaded disease before there’s even enough data to determine how valuable the drug really is. ICER has adopted this same strategy in the past on innovative drugs for cancer, cystic fibrosis, and other devastating diseases. This time ICER’s target is aducanumab, Biogen’s drug for Alzheimer’s disease.

Ever-larger rebates are distorting the market for branded drugs and producing outcomes that often benefit neither consumers nor the healthcare system, according to a new study published by Pioneer Institute.

Wide variation found in price of generics, less for brand-name drugs; consumers must navigate difficult terrain to find lowest price BOSTON – It’s far easier to get prescription drug price information than to get similar numbers from hospitals or specialty physicians, but...

Study: Requiring Drug Companies to Disclose Price Methodologies, Other Proprietary Information Would Discourage Drug Development, Lead to Higher Long-Term Healthcare Costs Promoting competition, looking more closely at healthcare price opacity would be more effective ways to limit cost inflation Read coverage of...